BMY Latest Press Releases

-- October 29, 2026 --

2027 Could Finally Be the Year Cancer Is on the Ropes! Globe Newswire 9:10 PM

Bristol Myers Squibb Reports Third Quarter Financial Results for 2026 Business Wire 6:59 AM

-- October 26, 2026 --

Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study Business Wire 3:30 AM

-- October 25, 2026 --

BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy Globe Newswire 3:30 AM

-- October 23, 2026 --

Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients with Highly Active Relapsing and Progressive Forms of Multiple Sclerosis at MSToronto 2026 Business Wire 10:30 AM

Tempus Expands Strategic Collaboration with Bristol Myers Squibb Business Wire 9:00 AM

Pathos AI Secures $237 Million in Series E Financing to Scale Agentic AI Drug Development Platform and Advance Oncology Pipeline Business Wire 9:00 AM

Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer's Disease and Other Neurological Conditions Business Wire 9:00 AM

Izalontamab Brengitecan (Iza-Bren) Reduced Risk of Disease Progression or Death by 59% versus Chemotherapy in Patients with Advanced HR+/HER2- Breast Cancer in Phase 3 PANKU-Breast01 Study Business Wire 7:30 AM

-- October 19, 2026 --

Bristol Myers Squibb to Showcase Next-Generation Cancer Modalities and Leadership Across Solid Tumors at ESMO 2026 Business Wire 6:59 AM

-- October 12, 2026 --

Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio's Radiopharmaceutical Therapy, in Patients with GEP-NETs Business Wire 6:55 AM

Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint Business Wire 6:50 AM

-- October 8, 2026 --

Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs. Standard of Care in Relapsed and Refractory Multiple Myeloma in Phase 3... Business Wire 6:59 AM

-- October 1, 2026 --

Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement Business Wire 6:59 AM

-- September 30, 2026 --

U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb's CAMZYOS (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients* Business Wire 5:32 PM

-- September 25, 2026 --

Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma Business Wire 10:00 AM

-- September 18, 2026 --

Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026 Business Wire 6:59 AM

-- September 17, 2026 --

Bristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years Business Wire 6:59 AM

-- September 16, 2026 --

Bristol Myers Squibb Announces Dividend Business Wire 6:59 AM

-- September 10, 2026 --

Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market Globe Newswire 8:30 AM

-- September 8, 2026 --

Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ... Business Wire 6:59 AM

-- August 29, 2026 --

Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026 Business Wire 11:00 AM

-- August 26, 2026 --

A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer's Biggest Opportunity Globe Newswire 9:20 AM

-- August 13, 2026 --

U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS , in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse Business Wire 5:12 PM

Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration PRNewswire 8:00 AM

-- August 10, 2026 --

Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas Business Wire 9:01 AM

-- July 30, 2026 --

Bristol Myers Squibb Reports Second Quarter Financial Results for 2026 Business Wire 6:59 AM

-- July 20, 2026 --

Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA Business Wire 6:59 AM

-- July 13, 2026 --

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma Business Wire 6:59 AM

-- June 24, 2026 --

The Quest to Repair What Multiple Sclerosis Takes Away Globe Newswire 8:30 AM

-- June 18, 2026 --

Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026 Business Wire 6:59 AM

-- June 17, 2026 --

Bristol Myers Squibb Announces Dividend Business Wire 4:16 PM

-- June 8, 2026 --

Mariska Hargitay Partners with Bristol Myers Squibb for "Investigating Myeloma" Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease Business Wire 6:59 AM

-- June 3, 2026 --

Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD-L1/VEGF-A Bispecific Immunomodulator to Treat Kidney Cancer Business Wire 8:00 AM

-- June 2, 2026 --

Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinoma Business Wire 8:00 AM

-- June 1, 2026 --

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) Business Wire 6:59 AM

Bristol Myers Squibb Announces Opdivo (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma Business Wire 6:55 AM

-- May 30, 2026 --

Global Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial Globe Newswire 2:15 PM